^
Association details:
| Biomarker: | CDA underexpression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | gemcitabine (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
Published date:
11/17/2021
Excerpt:
Low CDA transcript was prognostic regardless of arm; 24.8 v 21.2 months with gemcitabine (p = 0.02) and 26.4 v 14.6 months with 5-FU (p = 0.02)....For patients treated with gemcitabine, high CDA expressers had a median survival of 21.2 (95% CI = 15.7–26.2) months compared with 24.8 (95% CI = 18.3–33.0) months for low CDA expressers (Figure 2B, χ2 = 5.14, p = 0.02).
DOI:
10.3390/cancers13225758
